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Abstract

There is specific interest regarding the issue of hypertension management and
guidelines because of the recent news worthy item of decreases in goal blood pressures
established by the American Heart Association (AHA) and American College of Cardiology (ACC).
Young adults are of specific interest with regards to this subject because there is an estimated
35% of the population currently living with hypertension in the United States (Muntner, et al.
2018). Young adults are not typically the first population that comes to mind when thinking
about high blood pressure but essential hypertension often begins in the 20s to 30s with
problematic outcomes later in life. Hypertension in persons over 65 is widely understood for
increased risk of stroke and cardiac events but young adults (those aged 18-44) are not as well
studied (Johnson, et al. 2014b). The new guidelines for hypertension from the AHA/ACC
include a change from >140/>90 mm Hg as diagnostic for hypertension stage one to >130/>80
mm Hg. A ten point increase means roughly 30 million more adults in the United States will
meet criteria for stage one hypertension or higher. With the influx of newly diagnosed
individuals, HTN diagnosis, treatment, and management needs to include young adults as well
as older adults. Young adults should be routinely screened for HTN and a target goal of
<120/<80 mm Hg should be achieved for optimal health. Pharmacological interventions should
also be initiated for this population with the same regard as their elder peers (Whelton, et al.
2018).
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Stage One Hypertension Pharmacology Initiation for Young Adults
Background
Essential hypertension (HTN) is often referred to as the silent killer and is a medical
condition that plays a large role in the impact of other diagnosis and their progression towards
illness in the adult. HTN origination often begins at a younger age (20-40) because of various
genetic, hormonal, and lifestyle risk factors but is not recognized as a problem until the person
becomes older and has complications from the persistent elevations in blood pressure.
Uncontrolled HTN causes vasculature damage throughout the body system and has a great
impact on the bodies organs ability to work efficiently (Hamrahian, 2017). HTN is a huge
national concern and it affects approximately 75 million persons in the United States currently
and has an estimated economic impact of $51.2 billion dollars annually (Wang, Grosse, &
Schooley, 2017).
Current controversy exists in the medical guidelines regarding HTN diagnosis and
treatment because of the recent report made by the American Heart Association (AHA) and
American College of Cardiology (ACC). Prior to the statements made by the AHA and ACC, HTN
guidelines were referenced from the Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressures 7th and 8th reports (released in 2003 and
updated in 2014). The major changes made by the AHA and ACC suggest blood pressure
readings greater than 130mm Hg systolic and greater than 80 mm Hg diastolic as diagnostic for
HTN stage one compared to the previous 140/90 mm Hg in JNC 7 and 8 (Whelton, et al., 2017).
In the United States it is estimated that one third of the adult population has
hypertension and of those only 54% are well controlled. These individuals have a significant
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increase in their risk of developing heart disease and ultimately dying from a cardiac event or
stroke (Centers for Disease Control and Prevention 2018). Considering heart disease is
consistently among the highest diagnosis for mortality rates in the U.S., hypertension is a key
component to health prevention (Fang, Gillespie, Ayala, & Loustalot, 2018). According to the
new guidelines established by the AHA and ACC in late 2017 there will be an estimated 45.6% of
the population (over 100 million persons) that would qualify for a diagnosis of high blood
pressure with 36.2% of them being recommended to receive pharmacological intervention to
reduce their blood pressure (Muntner et al., 2018). Controversy remains in the literature about
the diagnosis and treatment of HTN in those age 65 or less. With a change to the recent
guidelines and the vast increases in younger persons being diagnosed with HTN, diagnostic
criteria and pharmacological interventions will need to be adapted.
Case Report
Patient information was obtained from a learning simulation during an on campus week
by author at the University of North Dakota. Patient identifiers are fictional and do not
represent an actual patient.
History
Jane is a 60 year-old Caucasian female that resides in our local community. She
presents to the clinic today for a three week follow up regarding a recent diagnosis of primary
hypertension during which she was started on Lisinopril 20mg daily. Prior non-pharmacological
interventions were unsuccessful in lowering her blood pressure below goal and she stated the
desire to begin medication for her HTN. In between her yearly physical appointments she was
instructed to increase her physical exercise, decrease sodium in her diet, and reduce stress in
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her life, which she states was too difficult with her busy schedule and caring for her
grandchildren. Over the last three weeks she has noticed that she has had a persistent dry
cough that is very irritating and bothersome to her. Blood pressure readings at home have
been obtained twice a day, in the morning before she takes her medication and in the evening
before bed. Her average blood pressure readings from her log are 145/85mm Hg with a high of
162/88mm Hg and a low of 141/76mm Hg. When questioned about her family history she
states that her brother and sister who are currently living both have had HTN for years and her
father passed away in his 70’s, which she thinks was because of “heart problems.” Her mother
is still living, and she denies any significant medical problems for her. Jane is a thirty pack year
former smoker having quit ten years ago, takes a daily multivitamin, consumes caffeine daily,
drinks three glasses of wine a week, no other significant medical history, and has no known
drug allergies.
Physical Examination/ Review of Symptoms
Upon examination Jane appears well-nourished, well-developed, and appears in no
acute distress. Her affect is appropriate and she is alert and oriented times four. Vitals signs
are as follows: BP 160/98, P 80, RR 20, O2 100% RA, T 98.6F, Weight of 163lbs BMI 27. Skin is
warm and dry while being free of rashes or lesions. Heart rate and rhythm are regular with
S1/S2 noted with no rubs, gallops, or murmurs. Lungs are clear to auscultation bilaterally and
are without adventitious sounds. Her cranial nerves are grossly intact. During questioning of
her review of symptoms she denies headaches, visual changes, fevers, chest pain, shortness of
breath, swelling, numbness/tingling, syncopal episodes, dizziness, and changes in mood. Other
significant review of symptom items are included in her history of present illness.
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Diagnosis
Patient continues to have elevated blood pressures at home as well as in the office
setting. Per the JNC 8 guidelines, goal blood pressure for this patient is <150/90mm Hg. Since
she is a 60 year-old with no other comorbidities, initial treatment should be with the use of an
ACEI, ARB, CCB, or a thiazide diuretic (Joseph, 2018). This patient is most likely suffering from a
cough induced by her ACE inhibitor and the best approach would be to stop her current
Lisinopril prescription.
Treatment/Follow Up
Jane will be instructed to stop her current medication of Lisinopril since it is the most
likely cause of her current cough and a new prescription of Losartan 50mg PO daily will be
initiated. A prescription for 81mg aspirin will also be started for this patient to reduce her risk
of cardiac events. She will follow up in three months to determine her blood pressure control
and adherence to the new medication regiment. Other education for patient would include
weekly home monitoring of blood pressure, limiting sodium in her diet, and medication
adherence. She should continue to not smoke and keep her alcohol consumption at or below
one ounces per day. Lab work for initiation of medication was noted from her yearly done
three weeks prior and kidney/liver function will be monitored at her yearly appointments
(Domino, Baldor, Golding, & Stephens, 2017).
Literature Review
Hypertension is estimated to begin in most adults around their twenties and thirties and
leads to a vast number of complications within the human body and is the most preventable
comorbidity that triggers death in the United States (Johnson et al, 2014b). Death from HTN
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and its implications occurs at an average of 1,000 persons every day and has most recently
taken nearly 400,000 American lives in the year 2013 (CDC, 2018). The largest concern for
elevated blood pressures across a lifespan is the impact it has on our cardiovascular system,
with financial burdens surpassing $300 billion per year (Wang, Grosse, & Schooley, 2017).
Longer periods of uncontrolled blood pressure equates to an increased risk of dying from a
cardiac event and 47% of all cardiac events worldwide are attributed to HTN. In the United
States there is an estimated 35% of persons under 65 who have HTN. Include this data with the
national changes in HTN guidelines, and we are guaranteed to nearly double the young adults
meeting the criteria for a HTN diagnosis and consideration for pharmacological intervention.
Young adults age 20-44 will see an increase from 10.5% with JNC 8 to 24% with AHA/ACC and
ages 45-54 jump 29.5% to 47.1% (Muntner et al., 2018). Another alarming factor is that this
special population has the worst blood pressure control at around 38% compared to elder
adults who are typically controlled >60% of the time. Poor control of HTN in the young adult
increases their risk of strokes, kidney disease, and a whole plethora of other life threatening
diseases throughout their lifetime (Johnson et al., 2014a).
Methodology
Literature was varied in the preference for early initiation of pharmacological
interventions, versus lifestyle modification approaches. Search strategies for my questions
began by using the University of North Dakota School of Medicine and Health Sciences library
database. From this database PubMed, CINAHL, and Cochrane were accessed because of their
ease of use and relevance to medical journal articles and studies. Using similar search
techniques for each database I began with the keywords addressed in my questioning of the

HYPERTENSION IN YOUNG ADULTS

9

case at hand. The keywords used for the searches were hypertension, young adult, disease
management, and pharmacology. In addition to the databases selected I also referenced major
organizations that are relevant to my research. The Centers for Disease Control and
Prevention, American Heart Association, American College of Cardiology, and the U.S.
Department of Health and Human Services Joint National Committee were all reviewed for
guideline standards as well. References were narrowed down to the last five years of
publishing and ten articles were selected for synthesis.
Synthesis of Current Literature
Three articles discussed HTN in the younger adult and the barriers they face in regards
to the evaluation, diagnosis, and treatment (including pharmacological interventions) often
seen with young adults and HTN. Young adults are in fact a unique population when it comes
to HTN because they currently account for 20% of the HTN criteria but are only being
monitored and controlled at a rate of 36%. Their non-compliance increases the risk for medical
costs, further complications, and mortality. This is especially interesting considering that once
young adults initiate antihypertensive medication they have relatively good control rates of
upwards of 70% (Johnson, Warner, Bartels, & LaMantia, 2017). Looking at the timing of
diagnosis in young adults in relationship to the guidelines criteria of a blood pressure of
>140/90 they also have a 33% slower diagnosis rate when compared to persons greater than
sixty, even with the same blood pressure numbers. (Johnson, et al. 2014b). A further barrier
this population faces is the ability to receive pharmacological interventions for their HTN
diagnosis. Young adults have a 44% slower initiation of pharmacological intervention when
compared to older adults. Some of the reasons as to why this occurs include limited education
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by the provider, prescriber error, and patient rejection (Johnson, et al. 2014a). Significant
barriers for the young adult exist because primary care providers are simply underserving them
with the notion that HTN is an old person’s disease. Primary care providers need to better
understand HTN control in the young adult in order to tailor their needs towards wellness and
longevity (Johnson, Warner, Bartels, & LaMantia, 2017). Providers also cannot assist in
prevention like previously stated if they are missing diagnosis on a regular basis with a
population that serves a large portion of individuals currently dealing with HTN (Johnson, et al.
2014b).
Another three articles tackled the issue of treatment for young adults once diagnosed
with HTN and the issue of what the new HTN guideline numbers were going to do to the
number of people being diagnosed. Findings were consistent with the belief that lower target
numbers equated to a higher prevalence of HTN for citizens. Nearly 45.6% of current
Americans are now considered to have HTN as compared to the 31.9% prior. The ten point
threshold for blood pressure equated to a 15% increase in individuals qualifying for HTN. These
numbers are alarming and mean many more young adults will be seeking medical attention for
treatment (Muntner, et al. 2018) Once these individuals have a diagnosis of HTN they need to
be monitored throughout a lifetime. An analysis of 2,990 patients from 18-39 concluded that
shorter follow-up times lead to greater blood pressure control overall. This is also important to
note because going against many of the other guidelines young adults are often seen the least
often. This could be one intervention to overcoming the barriers faced by young adults. One to
two month follow-up appointments resulted in 76% control compared to greater than six
months being 13% (King, et al. 2017). In a study done from 2011-2015 using data acquired from
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the Behavioral Risk Factor Surveillance System the researchers sought to understand HTN
diagnosis and medication requirements. Roughly half a million participants responded to these
surveys and 30% reported having been diagnosed with HTN and of those over 60% were on
medication (Fang, Gillespie, Ayala, & Loustalot, 2018). This survey helps solidify the increasing
proportion of overall adults having elevated blood pressures and the need for continued
support, interventions, and control.
The search within COCHRANE provided one systematic review that guided
pharmacology initiation for the young adult. For this review the authors addressed how HTN
treatment is well known in the adult greater than 60 but what about all the adults that fall
below this range? Their selection criteria for inclusion into the review had to be greater than
one year and compared HTN medication versus placebo in adults less than sixty-years old.
Their target blood pressure for goal was defined as less than 140/90 mm Hg. Overall, their
conclusions were that there is a small reduction in absolute effect in cardiac mortality but there
was no change in median mortality associated with cerebrovascular death. They suggest more
studies need to be performed on young and middle aged adults in order to accurately
determine antihypertensive use (specifically variations in medication classes) in this age group
to reduce cardiovascular complications (Musini, Gueyffier, Puil, Salzwedel, & Wright, 2017).
The most recent clinical guidelines for HTN as outlined by the ACC/AHA and JNC 8 as
well as a synopsis of current practice guidelines in 2018 dictate HTN goal treatment for young
adults. In regards to age specific populations the ACC/AHA recommend any persons under the
age of 60 should be initiating blood pressure lowering techniques to include pharmacological
interventions when needed for readings greater than 140/90 mm Hg. This goal, which is in line
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with the prior JNC 8 is only for adults who have no history of cardiovascular disease and whom
have a less than 10% risk of ASCVD risk (Whelton, et al. 2017). If the young adult were to have
any of these risk factors regardless of age their goal blood pressure would be the new standard
of 130/90 mm Hg (Whelton, et al. 2017). The JNC 8 findings for young adults had a similar
suggestion for pharmacological initiation in this population. In the otherwise healthy adult
medication should be started for readings greater than 140/90 mm Hg as well but this is solely
based on expert opinion and needs more randomized control trials within young adults to
warrant better grading (James, et al. 2014). Current practice guidelines reiterated the same
findings from JNC 8, AHA, ACC, and various other world organizations for young adults and
pharmacological interventions to treat HTN (Joseph, et al. 2018).
Learning Points/Conclusion
•

Blood pressure goals for patients 18-39 years old should be <120/<80 mm Hg.
o Current Organizations including the AHA and ACC have changed the diagnosis of
stage 1 essential hypertension to a blood pressure reading of >130/>80. This
change is likely to diagnosis 30 million more Americans than the previous
guidelines (Whelton, et al. 2018).

•

Age bias should be avoided at all costs when dealing with a diagnosis of HTN.
o Elevated blood pressures affect people of all ages and the sooner and more
frequently that it is detected and managed the greater the outcomes. It should
no longer be considered a disease of “the old” and therefore be monitored and
treated for all individuals. Only 36% of young adults diagnosed with HTN are
being treated currently (Johnson, Warner, Bartels, & LaMantia, 2017).
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Antihypertensive initiation and medication treatment options are consistent with
current guidelines in the young adult.
o Further studies need to address the young adult population with consideration
for pharmacological intervention to grasp a better understanding. Current
guidelines include the young adult In the initiation of blood pressure lowering
medicines and initiation beginning with numbers >140/>90 mm Hg (Whelton, et
al. 2018).
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